<DOC>
	<DOCNO>NCT02003924</DOCNO>
	<brief_summary>The purpose study assess safety efficacy enzalutamide patient non metastatic prostate cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Enzalutamide Patients With Nonmetastatic Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma prostate without neuroendocrine differentiation , signet cell , small cell feature ; Ongoing androgen deprivation therapy gonadotropinreleasing hormone ( GnRH ) agonist/antagonist prior bilateral orchiectomy ( medical surgical castration ) ; Testosterone ≤ 50 ng/dL ( ≤ 1.73 nmol/L ) screening ; Progressive disease androgen deprivation therapy enrollment ; PSA screen PSA assessed central laboratory ( central PSA ) ≥ 2 µg/L ( 2 ng/mL : PSA double time ≤ 10 month ; No prior present evidence metastatic disease ; Asymptomatic prostate cancer ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 ; Estimated life expectancy ≥ 12 month . Prior cytotoxic chemotherapy ; Use hormonal therapy biologic therapy prostate cancer ( approve bone target agent GnRH agonist/antagonist therapy ) use investigational agent within 4 week randomization ; Known suspect brain metastasis active leptomeningeal disease ; History another invasive cancer within 3 year randomization ; Absolute neutrophil count &lt; 1000/μL , platelet count &lt; 100,000/μL , hemoglobin &lt; 10 g/dL ( 6.2 mmol/L ) screening ; Total bilirubin ≥ 1.5 time upper limit normal ; Creatinine &gt; 2 mg/dL ( 177 µmol/L ) screening ; Albumin &lt; 3.0 g/dL ( 30 g/L ) screening ; History seizure condition may predispose seizure ; Clinically significant cardiovascular disease ; Gastrointestinal disorder affect absorption ; Major surgery within 4 week randomization ; Hypersensitivity reaction active pharmaceutical ingredient capsule component , include Labrasol , butylate hydroxyanisole , butylate hydroxytoluene ; Any concurrent disease , infection , comorbid condition interferes ability patient participate trial , place patient undue risk , complicate interpretation data , opinion investigator medical monitor .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>